



HL:MM:2018

November 1, 2018

General Manager – Listing, ISC & CRD
BSE Limited
Phiroj Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 51

Company Code No. : 524735

Symbol : HIKAL

Dear Sir/Madam,

Reg : **Investor Release on Financial Results for the quarter and half year ended
30th September 2018**

We are enclosing herewith the Investor Release on Unaudited Financial Results for the Quarter and Half Year ended 30th September 2018 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

This is for your information and record.

Thanking You,

Yours faithfully,
For Hikal Ltd.

Mukund Mujumdar
AGM - Secretarial

Encl : as stated above.

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. : +91-22-3097 3100. Fax : +91-22-3097 3281

Regd. Office: 717/718, Maker Chambers - V, 7th Floor, Nariman Point, Mumbai - 400 021, India. Tel. : +91-22-6630 1801 / 2283 4587 Fax : +91-22-2283 3913

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028




Hikal Limited

H1FY19 : Another Year of STRONG Performance

- ✓ Sales of Rs. 720 Crore; Growth of 29%
- ✓ EBITDA of Rs. 136 Crore; Growth of 31%
- ✓ PAT of Rs. 40 Crore; Growth of 41%

Mumbai, November 1st, 2018: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter ended 30th September, 2018.

Highlights for Half Year Ended 30th September, 2018



Performance highlights for the half year ended 30th September, 2018

- **Sales up 29% to Rs. 720 crore** as compared to Rs. 559 crore in the corresponding period of the previous year
- **EBITDA up 31% to Rs. 136 crore** as compared to Rs. 103 crore in the corresponding period of the previous year
- **PAT up 41% to Rs. 40 crore** as compared to Rs. 29 crore in the corresponding period of the previous year

Segmental Performance for the half year ended 30th September, 2018

- **Crop Protection sales up 26% to Rs. 293 crore** as compared to Rs. 233 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 31% to Rs. 428 crore** as compared to Rs. 326 crore in the corresponding period of the previous year



Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“We continue our growth momentum with a revenue increase of 29% and a PAT increase of 41% for the first half of the year. Our EBITDA margins have improved to 18.9% on higher volumes and realizations.

Our Pharmaceutical business has grown significantly by 31% and the Crop Protection business by 26% as compared to the first half of FY 2017'18. To meet the increased demand from our customers we debottlenecked our Pharmaceutical plants in the first quarter which enabled us to supply higher volumes based on the increased demand of our customers. Our crop protection business is also seeing a positive increase in volumes.

We completed a successful Audit by the Japanese Regulatory Agency at our Bangalore Pharmaceutical facility which should generate new opportunities in Japan in the near future. We are undertaking significant capital investment in both our businesses to meet the growing demand for existing and new products.

We are confident the growth momentum will continue in the second half of the year.”



About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi
anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave
payal.dave@sgapl.net
+91 9819916314

www.sgapl.net